Genetically determined factors that alter the metabolism of tobacco carcinogens can influence an individual's susceptibility to bladder cancer. The associations between the genotypes of glutathione S-transferase (GST) M1, GSTP1, GSTT1 and N-acetyltransferase (NAT) 1 and the phenotypes of NAT2 and cytochrome P450 (CYP) 1A2 and bladder cancer risk were examined in a case-control study involving 731 bladder cancer patients and 740 control subjects in Los Angeles County, California. Individual null/low-activity genotypes of GSTM1, GSTT1 and GSTP1 were associated with a 19-48% increase in odds ratio (OR) of bladder cancer. The strongest association was noted for GSTM1 [OR for the null genotype 5 1.48, 95% confidence interval (CI) 5 1.19-1.83]. When the three GST genes were examined together, there was a monotonic, statistically significant association between increasing number of null/ low-activity genotypes and risk (P for trend 5 0.002). OR (95% CI) for one and two or more null/low-activity GST genotypes was 1.42 (1.12-1.81) and 1.71 (1.25-2.34), respectively, relative to the absence of null/low-activity GST genotype. NAT2 slow acetylation was associated with doubled risk of bladder cancer among individuals with known high exposures to carcinogenic arylamines (OR 5 2.03, 95% CI 5 1.12-3.69, P 5 0.02). The effect of NAT2 slow acetylation was even stronger in the presence of two or more null/low-activity GST genotypes. There were no associations between bladder cancer risk and NAT1 genotype or CYP1A2 phenotype.
Introduction
Cigarette smoking is the most important known risk factor for urinary bladder cancer, accounting for $50% of all incident cases in the USA (1, 2) . Selected arylamines [including 2-naphthylamine, benzidine and 4-aminobiphenyl (4-ABP)] present in cigarette smoke and other environmental sources have been identified as human bladder carcinogens (3, 4) . Metabolic activation is required to biotransform these arylamines into their carcinogenic forms. The first step in this activation pathway is N-oxidation, which is catalyzed by the hepatic cytochrome P450 (CYP) 1A2 isoenzyme (5) . Large interindividual variation in CYP1A2 activity is seen in humans and thought to be the basis for genetically determined differences in susceptibility to urinary bladder cancer arising from exposures to arylamines. Phenotypic studies have suggested that CYP1A2 is regulated by at least two mechanisms: one that controls constitutive levels of expression and the other that regulates inducibility (6, 7) . No polymorphic sequences in the structural CYP1A2 gene that reflect interindividual differences in enzyme activity have been found. At present, CYP1A2-related activity can be phenotypically measured by assessing caffeine metabolites in urine after ingestion of caffeine (6, 8) .
Arylamines can be detoxified via N-acetylation catalyzed by N-acetyltransferases (NATs) in the liver. Humans' NATs are coded by two distinct genes, NAT1 and NAT2 (9) . NAT2 is primarily expressed in human liver, whereas NAT1 is detectable in both hepatic and extrahepatic tissues including bladder and colon (9, 10) . N-acetylation of arylamines, a competing detoxification pathway, is primarily controlled by hepatic NAT2. NAT2, a non-inducible enzyme, has long been known to exhibit polymorphism. In early phenotypebased studies, the slow acetylator phenotype was associated with increased risk of urinary tract cancer (11, 12) . Genotyping studies demonstrated that slow acetylators, particularly those who were exposed to cigarette smoke or arylamines under occupational settings, were at an increased risk for bladder cancer (13, 14) . However, studies conducted in USA populations have produced equivocal results (15, 16) .
Appreciable NAT1 but low NAT2 activities are seen in bladder epithelium (17) . O-acetylation of N-hydroxylamines catalyzed by NAT1 in the bladder leads to highly electrophilic N-acetoxy derivatives that can covalently bind to urothelial DNA, a critical step toward malignant cell transformation. Therefore, polymorphic NAT1 genotypes are thought to modulate an individual's susceptibility to bladder cancer (18) . Numerous polymorphisms in the NAT1 genes in human populations have been reported (19, 20) . Of particular interest is the NAT1 Ã 10 genotype, which has been associated with higher levels of NAT1 activity and DNA adducts in human bladder tissue (17) . Some studies found that NAT1 Ã 10 was overrepresented among bladder cancer patients (10, 15) . However, epidemiologic results are conflicting (21) .
The glutathione S-transferases (GSTs) comprise a supergene family of phase 2 detoxifying enzymes that catalyze the conjugation of xenobiotics, including aromatic hydrocarbons, chlorinated compounds and some heterocyclic amines, with glutathione, resulting in enhanced elimination of potential carcinogens (22) . Each class consists of one or more isoenzymes with different, but sometimes overlapping, substrate specificity. Genetic polymorphisms have been demonstrated for GSTM1, GSTT1 and GSTP1 genes. The homozygous deletion polymorphisms (i.e. null genotype) in the GSTM1 and GSTT1 genes, respectively, result in total abolishment of their respective enzyme activities in an individual (23) . A transition of adenine (A) to guanine (G) at nucleotide 313 in exon 5 of the GSTP1 gene results in substitution of isoleucine by valine at position 104 in the amino acid sequence (24) . The homozygous valine variant (i.e. GSTP1 BB genotype) exhibits lower specific activity and affinity for the electrophilic substrates of the enzyme (25) . Most population-based studies have found that the GSTM1 null genotype is associated with an increased risk of bladder cancer. Several epidemiologic studies have examined the associations between GSTT1 or GSTP1 genotypes and bladder cancer risk. Findings have been equivocal, with the null/low-activity genotypes showing increase, no association or decrease in bladder cancer risk (14, (26) (27) (28) (29) (30) .
The Los Angeles Bladder Cancer Study was a large-scale, populationbased case-control study involving mainly non-Hispanic white subjects (2, 31, 32) . The present study describes our findings on phenotypes/ genotypes of CYP1A2, NAT2, GSTM1, GSTP1, GSTT1 and NAT1 in relation to risk of bladder cancer among non-Hispanic white subjects.
Materials and methods

Study population
The design of the Los Angeles Bladder Cancer Study was described previously (2) . Case patients were non-Asians aged 25-64 years, diagnosed with Abbreviations: AAMU, 5-acetylamino-6-amino-3-methyluracil; 4-ABP, 4-aminobiphenyl; CI, confidence interval; CYP, cytochrome P450; GST, glutathione S-transferase; Hb, hemoglobin; MU, methyluracil; MX, methylxanthine; NAT, N-acetyltransferase; OR, odds ratio. (33) . Among 2384 eligible case patients, 210 (9%) died before we could contact them or were too ill to be interviewed; permissions to contact 99 (4%) patients were refused by their physicians and 404 (17%) patients refused to participate in the study. We interviewed the remaining 1671 (70%) bladder cancer patients.
For each case patient, we chose one control subject who was individually matched to the index case patient by gender, date of birth (±5 years), race (nonHispanic white, Hispanic white or African-American) and neighborhood of residence at the time of cancer diagnosis. The control subjects were identified by a standard procedure defining a sequence of houses on specified neighborhood blocks (2) . For the 1671 interviewed case patients, 1586 eligible control subjects were interviewed. Among them, 1090 (69%) were first eligible control subjects, 325 (20%) were second eligible control subjects, 111 (7%) were third eligible control subjects and the remaining 60 (4%) were fourth or higher order eligible control subjects. Permission to conduct the study has been obtained from the Institutional Review Boards at the University of Southern California and the University of Minnesota. Separate informed consent forms for interview and biospecimen collection were obtained from each study participant.
Data collection
A structured questionnaire was used during the in-person interview to request general and exposure information up to 2 years prior to cancer diagnosis for the case patients and 2 years prior to cancer diagnosis of the index case patients for the matched controls. Each subject was asked to report information on demographic characteristics, lifetime use of tobacco products and alcohol, usual adult dietary habits, lifetime occupational history, prior medical conditions and prior use of medications.
Starting from January 1992, all cases and their matched controls were asked additional questions regarding personal use of hair dyes and family history of cancer (34) . A supplemental questionnaire soliciting lifetime history of environmental tobacco smoke exposure also was administered to all case patients and control subjects who were non-current users of tobacco (35) .
Beginning in January 1992, all case patients (n 5 905) and control subjects (n 5 867) of non-Hispanic whites were asked to donate blood and an overnight urine sample. Seventy-three percent (662/905) case patients and 80% (690/867) control subjects consented to blood donation. All blood components (plasma, serum, buffy coat and red cells) were continuously stored at À80°C until analysis. The method for collection of urine samples has been described previously (36) . Briefly, all consenting subjects were given two packets of instant coffee ($70 mg of caffeine per packet) to be drunk between 3 and 6 p.m. The subject collected an overnight urine sample (ending with the first morning void) into a 1 l plastic bottle that was picked up and processed the same day. On the day of collection, the subject was briefly interviewed about caffeine intake (in addition to the prescribed packets of instant coffee) and use of acetaminophen on the previous day because excessive consumption of caffeine (.300 mg or more than four cups of coffee) or use of acetaminophen [an internal standard for the methylxanthin (MX) and urate assays] might affect the validity of the phenotyping assay (37) . We also asked subjects whether they used any tobacco products during the past 60 days. The urine specimens were acidified (400 mg of ascorbic acid per 20 mg of urine) prior to storage at À20°C (36).
Laboratory tests
Genotyping. Genomic DNA was isolated from blood lymphocytes. As described in detail previously (38) , a standard, multiplex polymerase chain reaction protocol was used to analyze for the presence or absence of the GSTM1 and GSTT1 genes. GSTP1 genotyping was performed according to the method described in Harries et al. (26) . Among subjects who donated blood samples (662 case patients and 690 control subjects), informative GSTM1, GSTT1 and GSTP1 genotypes were obtained in 662 (100%), 658 (99.4%) and 657 (99.2%) case patients and 686 (99.4%), 680 (98.6%) and 684 (99.1%) control subjects, respectively.
NAT1 genotyping was conducted at the National Institute of Environmental Health Science using a mutant primer polymerase chain reaction-restriction fragment length polymorphism method combined with an allele-specific assay as described previously for several published sequence variations in the 3# region of NAT1 near the putative polyadenylation signal. Details of this genotyping method have been provided in Bell et al. (39) . Specifically, we examined NAT1 Ã 4 (presumably the 'wild-type' allele that contains a 'T' at nucleotide 1088 and a 'C' at nucleotide 1095), NAT1 Ã 10 (T1088A, C1095A), NAT1 Ã 3 (C1095A) and NAT1 Ã 11 (a variant that contains a 9 bp deletion in the nucleotides 1065-1090). The rare non-functional NAT1 alleles (20) and other single-nucleotide polymorphisms in NAT1 were not analyzed in this study. Positive and negative control samples for each allele were run in each analysis batch. Samples with ambiguous restriction fragment length polymorphism patterns were repeated until resolved. Informative NAT1 genotypes were obtained in 649 (98.0%) case patients and 677 (98.1%) control subjects. Because the NAT1 Ã 10 allele contains an altered polyadenylation signal and has been associated with elevated levels of DNA adducts (17) , genotypes containing at least one NAT1 Ã 10 allele were defined as putative high-risk genotypes and were compared with other non-NAT1 Ã 10 genotypes.
Phenotyping. Urinary caffeine metabolites, namely 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-MX, 1-methyluracil (MU) and 1,7-methylxanthin, were measured by the following methods. Levels of AAMU in urine were determined by a modified procedure of Tang et al. (40) , using high-performance exclusion chromatography. Quantification of MX, MU and 1,7-methylxanthin in urine was performed according to a modified procedure of Grant et al. (41) . These analyses were performed with appropriate internal standards. Calibration curves were created during the analysis and used for calculation of concentrations of all analytes. Quality control urine samples spiked with a low, intermediate and high range of the calibration concentrations were analyzed intermittently during the sample runs. Based on the value of a ratio of following urinary caffeine metabolites-AAMU:(AAMU þ MX þ MU), subjects were classified as either slow (ratio ,0.34) or rapid (ratio .0.34) acetylators (42) . Similarly, the CYP1A2 index is based on a ratio of urinary metabolites of caffeine-(AAMU þ MX þ MU):1,7-methylxanthin (37) . Higher values of the CYP1A2 index reflect higher CYP1A2 activities. Tobacco is a known inducer of CYP1A2 (43) . Thus, as expected, subjects reporting cigarette use during the 60 days prior to urine collection showed significantly higher CYP1A2 values. We used the separate median values of the CYP1A2 index in smokers and non-smokers (4.53 for non-smokers and 8.51 for smokers) to classify subjects into the high (above median) or the low (below median) CYP1A2 activity group. Among subjects who collected overnight urine samples (642 case patients and 609 control subjects), measurements of caffeine metabolites were obtained on 635 (98.9%) case patients and 606 (99.5%) control subjects.
Statistical analysis
To maximize the sample size, we included all subjects (730 cases and 740 controls) with available data on any genotypes or phenotypes of interest for the present analysis. Among 730 cases, 567 (78%) had both genotypes (i.e. any of GSTM1, GSTP1, GSTT1 and NAT1) and phenotypes (NAT2 and CYP1A2) determined (i.e. provided both blood and urine samples), 95 (13%) had genotypes only and 68 (9%) had phenotypes only. The corresponding figures among controls were 554 (75%), 134 (18%) and 52 (7%). The chi-square test was used to examine differences in the distributions of categorical variables, and the t-test was used on continuous variables for comparisons between case patients and control subjects. Unconditional logistic regression models (44) were used to examine the associations between genotypes/phenotypes and risk of bladder cancer. The strength of an exposure-disease association was measured by the odds ratio (OR) and its corresponding 95% confidence interval (CI) and two-sided P value. We broke the original matched-pair design in order to maximize the numbers of cases and controls with known genotype values. In all logistic regression models, the matching factors (age, gender) and previously identified risk factors for bladder cancer in this database were included as covariates (2, 31, 34, 45) : level of education (high school or below, 1-4 years of college or graduate school or above), currently smoking (no, yes), number of cigarettes smoked per day, number of years of smoking, level of 4-ABPhemoglobin (Hb) adducts in tertile, use of non-steroidal anti-inflammatory drugs (non-users, ,1441 pills or !1441 pills used over lifetime), ever use of permanent hair dyes (no, yes) and ever held a high-risk job (truck, bus or taxi driver; hair dresser or barber and aluminum product worker) (no, yes). Data were analyzed for men and women separately and for both sexes combined. The associations between genetically determined factors and bladder cancer risk for women were comparable with those for men. Hence, all results presented were for both sexes combined. Statistical analyses were performed using the SAS version 9.1 (SAS Institute, Cary, NC) statistical software package. All P values are two sided. P , 0.05 was considered statistically significant.
Results
The present study included 731 bladder cancer cases with available genotypes and/or phenotypes of interest. Transitional cell carcinoma accounted for 94% (n 5 687) of total cancer cases. The remaining 6% cases consisted of 12 adenocarcinoma, 6 squamous cell cancer, 15 non-specified papilomas and 11 other or unknown histological type. The distribution of selected characteristics between case patients and control subjects is summarized in Table I . The mean age (standard deviation) of case patients at cancer diagnosis was 55.8 (7.2) years, and the corresponding figure for control subjects at the time of cancer Genetic determinants and bladder cancer diagnosis of the index case patient was 55.7 (8.2) years. Approximately 21% of case patients and similar percentage of control subjects were women. Case patients had on average a lower level of education than control subjects but comparable levels of alcohol intake. Cigarette smoking, level of 4-ABP-Hb adducts, occupational history and regular use of permanent hair dyes in women were previously identified risk factors for bladder cancer in this study population (2, 34, 45) .
The main effects of GST/NAT/CYP genotypes/phenotypes in relation to risk of bladder cancer in total subjects are summarized in Table II . The strongest association, which was statistically significant, was noted for GSTM1 (multivariable-adjusted OR 5 1.58, 95% CI 5 1.25-1.99). Individual null/low-activity genotypes of GSTM1, GSTT1 and GSTP1 were associated with 58, 24 and 12% increased risk of bladder cancer, respectively, following multivariable adjustment. When the three GST genes were examined together, there was a monotonic, statistically significant association between increasing number of null/low-activity genotypes (range, 0-3) and risk (P for trend 5 0.002) ( Table II) .
The NAT2 slow acetylators were associated with a statistically significant 26% increase in risk of bladder cancer (OR 5 1.26, 95% CI 5 1.00-1.57, P 5 0.046) after adjustment for age and sex. The multivariate-adjusted OR became statistically non-significant (OR 5 1.11, 95% CI 5 0.87-1.41). Neither NAT1 Ã 10 genotype nor CYP1A2 phenotype was associated with increased risk of bladder cancer in the present study (Table II) .
We examined the GST/NAT/CYP genotypes/phenotypes and risk associations according to subjects' smoking history and his/her levels of 4-ABP-Hb adducts (Table III) . The associations between individual and the composite GST genotypes and the NAT2 phenotype and risk of bladder cancer were uniformly stronger among individuals with known high exposure to carcinogenic arylamines, namely heavy smokers (!30 pack-years) and/or those possessing high levels of 4-ABP-Hb adducts (.30 pg/g Hb). In this subgroup of subjects, the OR (95% CI) for one and two to three versus zero null/low-activity GST genotypes was 2. 33 (1.29-4.22) and 3.35 (1.49-7.56 ), respectively The following subjects with missing information on genotypes or phenotypes were excluded from the relevant analysis: GSTM1 on 4 control subjects, GSTT1 on 4 case patients and 10 control subjects, GSTP1 on 5 case patients and 6 control subjects, summed GST index on 7 case patients and 15 controls, NAT1 on 18 case patients and 22 controls and NAT2 and CYP1A2 on 8 case patients and 3 controls. b ORs were derived from unconditional logistic regression models that included the following covariates: age (years), gender, level of education (high school or below, 1-4 years of college, graduate school or above), currently smoking (no, yes), number of cigarettes smoked per day, number of years of smoking, total number of non-steroidal anti-inflammatory drug pills used over lifetime (non-user, ,1441 and 1441þ), ever use of permanent hair dye (no, yes), ever held a high-risk job (no, yes) and 4-ABP-Hb adducts in tertile (a separate category was created for 65 cases and 53 controls with missing values who were included the multivariate analysis).
c See the Materials and Methods section for the definitions for the rapid/slow acetylators as well as for the low/high CYP1A2 index.
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(P for trend 5 0.002). The comparable figure for NAT2 slow versus rapid acetylation was 2.06 (1.21-3.49). The joint effect of NAT2 phenotype and GST genotypes in relation to bladder cancer risk is presented in Table IV . Among subjects with known high exposure to carcinogenic arylamines, NAT2 slow acetylation was associated with an increase in bladder cancer risk regardless of GST genotype profile. In contrast, among subjects with lower levels of exposure to carcinogenic arylamines, the association between NAT2 slow acetylation and increased bladder cancer risk was apparent only among those possessing the high-risk GST genotype profile (two or more null/low-activity genotypes of GSTM1, GSTT1 and GSTP1). This possible interaction effect was statistically borderline significant (P for interaction 5 0.09). The overall joint effect of NAT2 phenotype and GST genotypes on bladder cancer risk was most pronounced among subjects with known high exposure to carcinogenic arylamines. Compared with NAT2 rapid acetylators without null/low-activity GST genotype, individuals possessing the NAT2 slow acetylation phenotype and two or more null/low-activity GST genotype had an OR of 9.37 (95% CI 5 2.15-40.86) for bladder cancer based on a relatively small sample size (22 cases and three controls) (Table IV) .
We also examined the pair-wise effects of NAT1 Â GST, CYP1A2 Â GST, NAT2 Â NAT1, NAT1 Â CYP1A2 and NAT2 Â CYP1A2 genotypes/phenotypes on bladder cancer risk. There was no obvious synergism between these gene pairs and risk.
Discussion
Our study demonstrates that null/low-activity genotypes of the GSTM1, GSTT1 and GSTP1 loci independently contributed toward risk of bladder cancer in the host. The strongest association was noted for GSTM1. The magnitude of the GSTM1-bladder cancer association in the present study (OR 5 1.53) was comparable with earlier reports (14, 46, 47) . The GST genotypes-bladder cancer association was strongest among subjects with known high exposure to carcinogenic arylamines (namely heavy smoking and/or high level of 4-ABP-Hb adducts). These findings are biologically plausible. Cigarette smoking is recognized to be the most important risk factor for bladder cancer, point sources of bladder carcinogens-polycyclic aromatic hydrocarbons and arylamines in the USA population. GSTM1, and probably GSTT1 and GSTP1, participates in the detoxification of polycyclic aromatic hydrocarbon in promoting the conjugation of carcinogenic electrophiles with glutathione, thus enhancing excretion in the urine. We analyzed our data under the assumption that the effects of GSTM1, GSTT1 and GSTP1 on risk are additive in bladder cancer. It is important to note that separate univariate analysis of individual genes would misclassify individuals with null/low-activity genotypes of one gene into the group of non-null/high-activity genotype of the other. For example, among 518 bladder cancer patients with at least one GSTT1 allele in the present study, 290 had homozygous deletion of GSTM1 and 69 had homozygous low-activity allele of GSTP1. Prior epidemiologic studies performing univariate analyses of GSTT1 and GSTP1 yielded similar, null findings as in the present study. Studies that examined the combined effects of GSTM1 null, GSTT1 null and/or GSTP1 BB genotypes on risk generally noted stronger effects than GSTM1 null alone (28, 29, 48) . Thus, prior observations are supportive of our novel contention that GSTM1, GSTT1 and GSTP1 jointly contribute to the host's risk level of bladder cancer in an additive manner.
Hereditary difference in N-acetylation activity among individuals has been recognized for .50 years (49). Our study began in early 1990s, which was before the complete identification and characterization of genetic variants of the NAT2 gene (50) . Thus, a phenotypic assay was chosen for our study to determine subject's acetylator status, a common approach used before the genome era. An additional benefit for use of this caffeine-based assay was the simultaneous determination of both NAT2 and CYP1A2 phenotypes from a single assay on the same urine sample (42, 51) .
Numerous epidemiological studies across different populations have examined the role of NAT2 phenotype/genotype in relation to bladder cancer risk. A recent meta-analysis including .5000 bladder cancer cases showed a statistically significant 40% increase in risk of bladder cancer in individuals possessing the NAT2 slow-acetylation genotypes (14) . A case-control study of Caucasians in the USA reported an $30% increase in risk of bladder cancer for NAT2 slow acetylation genotypes overall and 2-fold increase in risk among heavy smokers (16) . The present study demonstrated that NAT2 slow acetylation phenotype plays a significant role in the risk of bladder cancer, especially among subjects with known high exposure to carcinogenic arylamines (i.e. heavy smoking and high levels of 4-ABP-Hb adducts).
Our study represents that, for the first time, NAT2 acetylation status is examined in combination with a composite index of GST genotypes that presumably capture greater impact of the three GST genes on bladder cancer development. Our results suggest a potential modifying effect between NAT2 and the GSTs among subjects with no or low exposure to carcinogenic arylamines (i.e. light smokers and/or low levels of 4-ABP-Hb adducts), although the test for multiplicative effect was not statistically significant (P 5 0.09) given relatively small sample size. Among individuals possessing an unfavorable GST genotype profile, NAT2 slow acetylation status shows an $60% (i.e. the ratio of 1.77 over 1.12 5 1.58, 95% CI 5 0.80-1.35) increase in risk for bladder cancer, whereas no risk increase for NAT2 slow acetylation status was seen for subjects with more favorable GST genotypes.
The role of NAT1 gene in the etiology of bladder cancer is controversial. Taylor et al. (15) reported a statistically significant increase in risk of bladder cancer associated with the NAT1 Ã 10 genotype among heavy smokers in the USA. However, a later study in Germany reported a reduced risk of bladder cancer associated with the NAT1 Ã 10 genotype, especially among non-smokers or those who never held high-risk occupations (21) . A recent meta-analysis including .2500 bladder cancer cases and similar number of controls reported a null association between putative rapid NAT1 genotypes and risk of bladder cancer (52) . Our findings of a null association between the NAT1 Ã 10 genotype and bladder cancer risk was consistent with most epidemiologic studies across different populations (14, 16, 53, 54) . Earlier, we had reported that levels of 4-ABP-Hb adducts were comparable between individuals with and without the putative high-risk NAT1 Ã 10 genotype (55) . While NAT1 appears to play a role in the metabolism of aromatic amines, the relationship between NAT phenotype and NAT1 Ã 10 genotype remains uncertain and it is not surprising that the overall effect of NAT1 genotype on risk is negligible.
High CYP1A2 activity has been linked to elevated urinary mutagenicity in smokers (56, 57) and high 4-ABP-Hb adduct levels (58), a marker associated with increased risk of bladder cancer (45) . CYP1A2 activity in humans appears to be determined by both heritable and environmental factors. So far, all genetic polymorphisms identified in the CYP1A2 gene are located either in the 5# flanking regulatory region or the introns (59) (60) (61) (62) (63) . Neither individual singlenucleotide polymorphisms nor haplotypes could unequivocally predict the CYP1A2 metabolic phenotype in humans (62) (63) (64) (65) . Several environmental factors have been found to influence hepatic CYP1A2 expression and activity. Cigarette smoking (43, 66, 67) , consumption of high-temperature cooked meat (7) and cruciferous vegetables (68, 69) can enhance, whereas use of oral contraceptives (43, 67, 70) reduces CYP1A2 metabolic capacity.
Two epidemiologic studies have examined the association between the CYP1A2 phenotype and risk of bladder cancer. A casecontrol study involving 100 bladder cancer patients and 84 control subjects from an Asian population reported a statistically significantly higher capacity for 3-demethylation of theophylline, a marker for CYP1A2 activity, than control subjects (71), whereas a casecontrol study of 53 bladder cancer patients and 96 control subjects in a Canadian population (.90% of subjects were Caucasians) did not find any difference in plasma or urinary indices of CYP1A2 activity between bladder cancer patients and control subjects (72) . The present study with a larger sample size (635 case patients and 606 control subjects) did not detect any effect of the CYP1A2 index on risk of bladder cancer.
Genetic determinants and bladder cancer
The present study had several strengths including population-based study design, relatively large sample size and homogenous study population (non-Hispanic whites only). The comprehensive assessment of environmental exposures including smoking, occupation and personal use of permanent hair dyes allows for controlling for their potential confounding effect on the associations between genotypes and phenotypes of interest and risk of bladder cancer. More importantly, the measurement of 4-ABP-Hb adducts, a validated The high-exposure group consisted of smokers of !30 pack-years with high level of 4-ABP-Hb adducts (.30 pg/g Hb), whereas the low exposure group included all other subjects who never smoked or smoked ,30 pack-years of cigarettes or had a relatively low level of 4-ABP-Hb adducts ( 30 pg/g Hb).
b The number of bladder cancer patients/number of control subjects; subjects with missing information on genotypes or phenotypes listed in the footnote of Table II were excluded from the relevant analysis. In addition, 65 bladder cancer patients and 53 control subjects with unknown 4-ABP-Hb adducts were excluded from the subgroup analyses stratified by 4-ABP-Hb adducts alone or in combination of cigarette smoking. ORs were derived from unconditional logistic regression models that included the following covariates: age (years), gender, level of education (high school or below, 1-4 years of college, graduate school or above), number of cigarettes smoked per day, number of years of smoking, total number of non-steroidal antiinflammatory drug pills used over lifetime (non-user, ,1441 and 1441þ), ever use of permanent hair dyes (no, yes), ever held a high-risk job (no, yes) and 4-ABPHb adducts in tertile (a separate category was created for 65 cases and 53 controls with unknown 4-ABP-Hb adducts who were included in the subgroup analyses stratified by pack-years of smoking alone). d One was assigned to the GSTM1 null, GSTP1 BB or GSTT1 null genotypes, respectively, whereas zero was assigned to the GSTM1 non-null, GSTP1 AA or AB or GSTT1 non-null genotypes, respectively. biomarker for exposure to bladder carcinogens-arylamines, enhanced our ability for controlling the potential confounding effect of 4-ABP from various, as-yet-unidentified sources on the genotype/phenotype-bladder cancer association. Another strength of the present study was the determination of NAT2 and CYP1A2 status based on phenotype-based assays, which presumably represent their 'true' enzyme activity determined by both endogenous (i.e. genetic) and exogenous (i.e. environmental) factors. On the other hand, this phenotype-based approach has inherent limitation to distinguish the genetically determined effect from environmental influence on the respective enzymes, especially in the case of a large number of environmental factors that potentially affect the enzyme phenotype. For example, paraxanthine, isoniazid and sulfamethzine are substrates of NAT2. Several environmental factors have been found to influence hepatic CYP1A2 expression and activity. Cigarette smoking (43, 66, 67) , consumption of high-temperature cooked meat (7) and cruciferous vegetables (68, 69) can enhance, whereas use of oral contraceptives (43, 67, 70) reduces CYP1A2 metabolic capacity. Therefore, incomplete assessment and controlling for these environmental factors could lead to the misclassification of NAT2 and CYP1A2 phenotype status. In summary, this study confirms the role of GSTM1 in bladder cancer and is the first study suggesting that the null/low-activity genotypes of the GSTM1, GSTT1 and GSTP1 may additively contribute to risk of bladder cancer in the host. NAT2 slow acetylation status is related to increased risk of bladder cancer among subjects with known high exposure to carcinogenic arylamines. The present study also suggests a potential modifying effect between NAT2 and GST genes on bladder cancer, especially among subjects with exposure to carcinogenic arylamines.
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